THE Pharmaceutical Benefits Advisory Committee (PBAC) will convene a Special Meeting on 17 Aug 2018 to consider options for listing programmed death-ligand 1 (PDL1) cancer immunotherapies for the treatment of multiple tumours on the Pharmaceutical Benefits Scheme.
The meeting is being organised in response to a formal request from Health Minister Greg Hunt.
The PBAC has noted that while it is likely that PDL1 inhibitors will be useful for treating a range of cancers, limited trial results to date suggest that treatment responses are not uniform across different types of cancers, different age groups and different patient populations.
A background paper is being prepared in the lead-up to the meeting - expressions of interest to PBAC@health.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 30 Apr 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Apr 18
